{"id":"NCT01420627","sponsor":"Leadiant Biosciences, Inc.","briefTitle":"EZN-2279 in Patients With ADA-SCID","officialTitle":"A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-24","primaryCompletion":"2018-04-10","completion":"2019-05-29","firstPosted":"2011-08-19","resultsPosted":"2020-04-16","lastUpdate":"2020-04-16"},"enrollment":7,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ADA-SCID","Adenosine Deaminase Deficiency","Severe Combined Immunodeficiency"],"interventions":[{"type":"BIOLOGICAL","name":"EZN-2279","otherNames":["rADA"]},{"type":"BIOLOGICAL","name":"Adagen","otherNames":[]}],"arms":[{"label":"Adagen/EZN-2279","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.","primaryOutcome":{"measure":"Number of Patients Detoxified At Each Visit in EZN-2279 Treatment Period","timeFrame":"Baseline through Week T-21","effectByArm":[{"arm":"EZN-2279","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Vomiting","Cough","Non-cardiac chest pain","Pyrexia","Diarrhoea"]}}